Rufinamide: A new antiepileptic medication for the treatment of seizures associated with Lennox-Gastaut syndrome

Annals of Pharmacotherapy

Volumn 44, Issue 4, 2010, Pages 658-667

  Wisniewski, Christopher S ^a,b  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Epilepsy; Lennox gastaut syndrome; Rufinamide

Indexed keywords

ANTICONVULSIVE AGENT; BANZEL; BROMIDE; CARBAMAZEPINE; CLOBAZAM; CLONAZEPAM; ETHOSUXIMIDE; ETIRACETAM; FELBAMATE; GABAPENTIN; LAMOTRIGINE; MESUXIMIDE; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; PLACEBO; PRIMIDONE; RUFINAMIDE; SODIUM CHANNEL; SULTIAME; TOPIRAMATE; UNCLASSIFIED DRUG; VALPROIC ACID; VIGABATRIN; ZONISAMIDE;

APLASTIC ANEMIA; ATAXIA; CELL MEMBRANE; CLINICAL TRIAL; COGNITION; COGNITIVE DEFECT; COMPARATIVE STUDY; COORDINATION DISORDER; DIZZINESS; DRUG ABSORPTION; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG EXCRETION; DRUG LABELING; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG USE; DRUG WITHDRAWAL; FATIGUE; FEVER; FOCAL EPILEPSY; GENERALIZED EPILEPSY; HEADACHE; HEALTH CARE COST; HEPATITIS; HUMAN; INFORMATION; KIDNEY; LENNOX GASTAUT SYNDROME; MEDICAL LITERATURE; MEDLINE; MORBIDITY; MULTIPLE ORGAN FAILURE; NAUSEA; PATIENT COUNSELING; PRIORITY JOURNAL; PUBLICATION; RASH; RETROSPECTIVE STUDY; REVIEW; SEIZURE; SOMNOLENCE; URTICARIA; VOMITING;

AGED; ANTICONVULSANTS; CHEMISTRY, PHARMACEUTICAL; CHILD; CLINICAL TRIALS, PHASE III AS TOPIC; COUNSELING; DRUG RESISTANCE; EPILEPSIES, PARTIAL; EPILEPSY; HUMANS; OFF-LABEL USE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEIZURES; SYNDROME; TRIAZOLES;

EID: 77950626042     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1M679     Document Type: Review

References (38)

1. Ferrie CD, Patel A. Treatment of Lennox-Gastaut syndrome (LGS). Eur J Paediatr Neurol 2009;13:493-504. DOI 10.1016/j.ejpn.2008.12.005
2. Hancock EC, Cross HHJ. Treatment of Lennox-Gastaut syndrome. Cochrane Database Syst Rev 2009;3:CD003277. DOI 10.1002/14651858.CD003277.pub2
3. Arzimanoglou A, French J, Blume WT, et al. Lennox-Gastaut syndrome: a consensus approach on diagnosis, assessment, management, and trial methodology. Lancet Neurol 2009;8:82-93.
4. Saneto RP, Anderson GD. Onset of action and seizure control in Lennox-Gastaut syndrome: focus on rufinamide. Ther Clin Risk Manage 2009; 5:271-280
5. Kluger G, Bauer B. Role of rufinamide in the management of Lennox-Gastaut syndrome (childhood epileptic encephalopathy). Neuropsychiatr Dis Treat 2007;3:3-11. (Pubitemid 46804298)
6. Cheng-Hakimian A, Anderson GD, Miller JW. Rufinamide: pharmacology, clinical trials, and role in clinical practice. J Clin Pract 2006;60: 1497-1501 (Pubitemid 44560351)
7. Hakimian S, Cheng-Hakimian A, Anderson GD, Miller JW. Rufinamide: a new anti-epileptic medication. Expert Opin Pharmacother 2007;8:1931-1940 (Pubitemid 47321524)
8. Prescribing information. Rufinamide (Banzel). Woodcliff Lake, NJ: Eisai Co., Ltd., November 2008.
9. Perucca E, Cloyd J, Critchley D, Fuseau E. Rufinamide: clinical pharmacokinetics and concentration-response relationships in patients with epilepsy. Epilepsia 2008;49:1123-1141 (Pubitemid 351991401)
10. Waldmeier F, Gschwind H, Rouan M, Sioufi A, Czendlik C. Metabolism of the new anticonvulsant trial drug rufinamide (CGP 33101) in healthy male volunteers (abstract 6.60). Epilepsia 1996;37:167.
11. Cheung WK, Kianifard F, Wong A, et al. Intra- and inter-subject variabilities of CGP 33101 after replicate single oral doses of two 200-mg tablets and 400-mg suspension. Pharm Res 1995;12:1878-1882 (Pubitemid 26032294)
12. Brunner LA, Harrigan EP, John VA, Powell ML. Pharmacokinetics of a new anticonvulsant (CGP 33101) in epileptic male patients and healthy male subjects after single ascending oral doses of 400-1200 mg. Am J Ther 1994;1:215-220
13. Cardot JM, Lecaillon JB, Czendilik C, Godbillon J. The influence of food on the disposition of the antiepileptic rufinamide in healthy volunteers. Biopharm Drug Dispos 1998;19:259-262
14. Kapeghian JC, Madan A, Parkinson A, Tripp SL, Probst A. Evaluation of rufinamide (CGP 33101), a novel anticonvulsant, for potential drug interactions in vitro (abstract 1.96). Epilepsia 1996;37:26.
15. Sachdeo RC, Rosenfeld WE, Choi L, Yeh CM, Cooper AN, Karolchyk MA. Pharmacokinetics and safety of adjunctive rufinamide therapy in pediatric patients with epilepsy (abstract 5.081). Epilepsia 1998;39:166-167
16. Chang SW, Choi L, Karolchyk MA. A pharmacokinetic evaluation of rufinamide in elderly and younger subjects (abstract 2.110). Epilepsia 1998;39: 59.
17. Critchley D, Fuseau E, Perdomo C, Arroyo S. Pharmacokinetic and pharmacodynamic parameters of adjunctive rufinamide in patients with Lennox-Gastaut syndrome (abstract 2.351). Epilepsia 2005;46:209.
18. Glauser T, Kluger G, Sachdeo R, Krauss G, Perdomo C, Arroyo S. Rufinamide for generalized seizures associated with Lennox-Gastaut syndrome. Neurology 2008;70:1950-1958
19. Pålhagen S, Canger R, Henriksen O, van Parys JA, Rivière ME, Karolchyk MA. Rufinamide: a double-blind, placebo-controlled proof of principle trial in patients with epilepsy. Epilepsy Res 2001;43:115-124 (Pubitemid 32115522)
20. Brodie MJ, Rosenfeld WE, Vazquez B, et al. Rufinamide for the adjunctive treatment of partial seizures in adults and adolescents: a randomized placebo-controlled trial. Epilepsia 2009;50:1899-1909
21. Glauser T, Kluger G, Sachdeo R, Krauss G, Perdomo C, Arroyo S. Open-label extension study of the efficacy and safety of rufinamide adjunctive therapy in patients with Lennox-Gastaut syndrome (abstract p1356). Epilepsia 2005;46:408.
22. Biton V, Sachdeo R, Rosenfeld W, Schachter S, Perdomo C, Arroyo S. Efficacy and safety of adjunctive rufinamide in patients with inadequately controlled primary generalized tonic-clonic seizures (abstract 2.343). Epilepsia 2005;46:206.
23. Elger C, Stefan H, Perdomo C, Arroyo S. Dose-range relationships of rufinamide in patients with inadequately controlled partial seizures (abstract p539). Epilepsia 2006;47:140.
24. Glauser T, Arzimanoglou A, Litzinger M, et al. Efficacy and safety of rufinamide as adjunctive therapy for inadequately controlled partial seizures in pediatric patients (abstract 2.309). Epilepsia 2005;46:194-195
25. Lesser RP, Biton V, Sackellares C, Van Ness PC, Perdomo C, Arroyo S. Efficacy and safety of rufinamide monotherapy for the treatment of patients with refractory partial seizures (abstract 2.258). Epilepsia 2005;46: 177-178
26. Todorov A, Biton V, Krauss GL, Perdomo C, Arroyo S. Efficacy and safety of high-versus low-dose rufinamide monotherapy in patients with inadequately controlled partial seizures (abstract 2.378). Epilepsia 2005;46:218-219
27. Aldenkamp AP, Alpherts WCJ. The effect of the new antiepileptic drug rufinamide on cognitive functions. Epilepsia 2006;47:1153-1159
28. Kluger G, Kurlemann G, Haberlandt E, et al. Effectiveness and tolerability of rufinamide in children and adults with refractory epilepsy: first European experience. Epilepsy Behav 2009;14:491-495
29. Krauss GL, Perdomo CA, Arroyo A. Short and long-term safety of rufinamide in patients with epilepsy (abstract 2.363). Epilepsia 2005;46:213.
30. Yu AS, Keeffe EB. Liver transplantation. In: Hepatology: a textbook of liver disease. 4th ed. Philadelphia: Elsevier Science, 2003:1617-1656
31. Fuseau E, Critchley D, Perdomo C, Arroyo S. Population pharmacokinetic drug-drug interaction analyses of rufinamide studies in patients with epilepsy (abstract 2.356). Epilepsia 2005;46:210-211
32. Svendsen KD, Choi L, Chen BL, Karolchyk MA. Single-center, open-label, multiple-dose pharmacokinetic trial investigating the effect of rufinamide administration on Ortho-Novum 1/35 in healthy women (abstract 2.111). Epilepsia 1998;39:59.
33. Prescribing information. Felbamate (Felbatol). Somerset, NJ: Meda Pharmaceuticals, Inc., June 2008.
34. Prescribing information. Lamotrigine (Lamictal). Research Triangle Park, NC: GlaxoSmithKline, May 2009.
35. Prescribing information. Topiramate (Topamax). Titusville, NJ: OrthoMcNeil-Janssen Pharmaceuticals, Inc., May 2009.
36. 2009 Drug topics red book. Montvale, NJ: Medical Economics, 2009.
37. Drugstore.com. Drug pricing. Topiramate - 25 mg sprinkle capsule. http://www.drugstore.com/pharmacy/prices/drugprice.asp?ndc=00093733606&trx= 1Z500 (accessed 2010 Jan 5).
38. Drugstore.com. Drug pricing. Topiramate - 100 mg tablets. http://www.drugstore.com/pharmacy/prices/drugprice.asp?ndc=00093721906&trx= 1Z5006 (accessed 2010 Jan 5).